CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
teexercise stress. Ranolazine is approved for use in the European Union asadd-on therapy for the symptomatic treatment of patients with stable anginapectoris who are inadequately controlled or intolerant to first-lineantianginal therapies.
Date:7/22/2008